Amidst Increasing Losses, Investors Bid up Xencor (NASDAQ:XNCR) 14% This Past Week
While not a mind-blowing move, it is good to see that the Xencor, Inc. (NASDAQ:XNCR) share price has gained 26% in the last three months. But that cannot eclipse the less-than-impressive returns ov
Insider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells Shares
Xencor Is Maintained at Buy by BTIG
Xencor Is Maintained at Buy by BTIG
Express News | BTIG Maintains Buy on Xencor, Lowers Price Target to $38
Xencor Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 98.28% BTIG $56 → $38 Maintains Buy 02/28/2024 25.23% Piper Sandler $37 → $24 Downgrades Overwe
Express News | Xencor Inc : Btig Cuts Target Price to $38 From $56
Xencor Inc Announces CFO Transition and Executive Compensation Plan
Xencor Appoints Bart Cornelissen As Chief Financial Officer >XNCR
Xencor Appoints Bart Cornelissen As Chief Financial Officer >XNCR
Don't Ignore The Insider Selling In Xencor
Anyone interested in Xencor, Inc. (NASDAQ:XNCR) should probably be aware that the Co-Founder, Bassil Dahiyat, recently divested US$294k worth of shares in the company, at an average price of US$23.43
Insider Sell: SR. VICE PRESIDENT & CFO John Kuch Sells 4,474 Shares of Xencor Inc (XNCR)
Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)
Xencor(XNCR.US) Director Sells US$324.45K in Common Stocks
$Xencor(XNCR.US)$ Director GUSTAFSON KURT A sold 14,000 shares of Common Stocks on Mar 6, 2024 at an average price of $23.1752 for a total value of $324.45K.Source: Announcement What is statement of c
Xencor Insider Sold Shares Worth $293,519, According to a Recent SEC Filing
Bassil I Dahiyat, Director, President & CEO, on March 05, 2024, sold 12,528 shares in Xencor (XNCR) for $293,519. Following the Form 4 filing with the SEC, Dahiyat has control over a total of 300,097
Improved Revenues Required Before Xencor, Inc. (NASDAQ:XNCR) Stock's 27% Jump Looks Justified
Xencor, Inc. (NASDAQ:XNCR) shares have had a really impressive month, gaining 27% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the losses of the l
Health Check: How Prudently Does Xencor (NASDAQ:XNCR) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, whe
Xencor's Strategic Focus and Pipeline Progress Affirm Buy Rating
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at
Xencor Cut to Neutral From Overweight by Piper Sandler
Xencor Cut to Neutral From Overweight by Piper Sandler
Piper Sandler Downgrades Xencor to Neutral, Lowers Price Target to $24
Piper Sandler analyst Edward Tenthoff downgrades Xencor (NASDAQ:XNCR) from Overweight to Neutral and lowers the price target from $37 to $24.
Xencor Down Over 10%, on Pace for Largest Percent Decrease Since September 2020 -- Data Talk
Xencor, Inc. ( XNCR ) is currently at $23.76, down $2.76 or 10.41% --Would be lowest close since Feb. 20, 2024, when it closed at $23.50 --On pace for largest percent decrease since Sept. 21, 2020,
No Data